Hartlapp, I, Valta-Seufzer, D., Siveke, J. T., Algul, H., Goekkurt, E., Siegler, G., Martens, U. M., Waldschmidt, D., Pelzer, U., Fuchs, M., Kullmann, F., Boeck, S., Ettrich, T. J., Held, S., Keller, R., Anger, F., Germer, C. T., Stang, A., Kimmel, B., Heinemann, V and Kunzmann, V (2022). Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113). ESMO Open, 7 (4). AMSTERDAM: ELSEVIER. ISSN 2059-7029

Full text not available from this repository.

Abstract

Background: The prognostic and predictive value of carbohydrate antigen 19-9 (CA 19-9) in locally advanced pancreatic cancer (LAPC) has not yet been defined from prospective randomized controlled trials (RCTs). Patients and methods: A total of 165 LAPC patients were treated within the NEOLAP RCT for 16 weeks with multiagent induction chemotherapy [ICT; either nab-paclitaxel/gemcitabine alone or nab-paclitaxel/gemcitabine followed by FOLFIRINOX (combination of fluorouracil, leucovorin, irinotecan, and oxaliplatin)] followed by surgical exploration of all patients without evidence of disease progression. CA 19-9 was determined at baseline and after ICT and correlated with overall survival (OS) and secondary R0 resection rate. Results: From the NEOLAP study population (N = 165) 133 patients (81%) were evaluable for CA 19-9 at baseline and 81/88 patients (92%) for post-ICT CA 19-9 response. Median OS (mOS) in the CA 19-9 cohort (n = 133) was 16.2 months [95% confidence interval (CI) 13.0-19.4] and R0 resection (n = 31; 23%) was associated with a significant survival benefit [40.8 months (95% CI 21.7-59.8)], while R1 resected patients (n = 14; 11%) had no survival benefit [14.0 (95% CI 11.7-16.3) months, hazard ratio (HR) 0.27; P = 0.001]. After ICT most patients showed a CA 19-9 response (median change from baseline: -82%; relative decrease >= 55%: 83%; absolute decrease to <= 50 U/ml: 43%). Robust CA 19-9 response (decrease to <= 50U/ml) was significantly associated with mOS [27.8 (95% CI 18.4-37.2) versus 16.5 (95% CI 11.7-21.2) months, HR 0.49; P = 0.013], whereas CA 19-9 baseline levels were not prognostic for OS. Multivariate analysis demonstrated that a robust CA 19-9 response was an independent predictive factor for R0 resection. Using a CA 19-9 decrease to <= 61 U/ml as optimal cut-off (by receiver operating characteristic analysis) yielded 72% sensitivity and 62% specificity for successful R0 resection, whereas CA 19-9 nonresponders (<20% decrease or increase) had no chance for successful R0 resection. Conclusions: CA 19-9 response after multiagent ICT provides relevant prognostic and predictive information and is useful in selecting LAPC patients for explorative surgery.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Hartlapp, IUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Valta-Seufzer, D.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Siveke, J. T.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Algul, H.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Goekkurt, E.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Siegler, G.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Martens, U. M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Waldschmidt, D.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pelzer, U.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fuchs, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kullmann, F.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Boeck, S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ettrich, T. J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Held, S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Keller, R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Anger, F.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Germer, C. T.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Stang, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kimmel, B.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Heinemann, VUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kunzmann, VUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-694699
DOI: 10.1016/j.esmoop.2022.100552
Journal or Publication Title: ESMO Open
Volume: 7
Number: 4
Date: 2022
Publisher: ELSEVIER
Place of Publication: AMSTERDAM
ISSN: 2059-7029
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
FOLFIRINOX; GEMCITABINE; BORDERLINE; CA19-9; ADENOCARCINOMA; RESECTION; SURVIVAL; OUTCOMES; CHEMORADIOTHERAPY; CHEMORADIATIONMultiple languages
OncologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/69469

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item